Rafferty Asset Management’s Nuvation Bio NUVB Stock Holding History
Bought
Maintained
Sold
Other funds holding NUVB
DC
OFM
LCM
DFO
Rafferty Asset Management's NUVB Position: Q2 2026 in Review
Rafferty Asset Management increased its Nuvation Bio (NUVB) stake by 36% in Q2 2026, buying an estimated $55.8K and bringing the position to 43,371 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #1053.
Rafferty Asset Management first reported a position in NUVB in Q3 2021 and has held it in 12 quarters since. The position peaked at $267K in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.
- Rafferty Asset Management held 43,371 shares of Nuvation Bio worth $246K as of Q2 2026.
- Rafferty Asset Management bought 11,407 Nuvation Bio shares in Q2 2026, an estimated $55.8K.
- Nuvation Bio made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1053 holding.
- Rafferty Asset Management first reported a position in Nuvation Bio in Q3 2021 and has held it in 12 quarters since.
- Rafferty Asset Management's Nuvation Bio position peaked at $267K in Q4 2025.
- 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.
Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.